Extending the Therapeutic Potential: Romosozumab in Osteoporosis Management.

Autor:	Liu L; Department of Diabetes and Endocrinology, Royal North Shore Hospital, Sydney 2065, Australia., Clifton-Bligh RJ; Department of Diabetes and Endocrinology, Royal North Shore Hospital, Sydney 2065, Australia.; Faculty of Medicine and Health, University of Sydney, Sydney 2006, Australia., Girgis CM; Faculty of Medicine and Health, University of Sydney, Sydney 2006, Australia.; Department of Diabetes and Endocrinology, Westmead Hospital, Sydney 2145, Australia., Gild ML; Department of Diabetes and Endocrinology, Royal North Shore Hospital, Sydney 2065, Australia.; Faculty of Medicine and Health, University of Sydney, Sydney 2006, Australia.
Jazyk:	angličtina
Zdroj:	Journal of the Endocrine Society [J Endocr Soc] 2024 Sep 13; Vol. 8 (11), pp. bvae160. Date of Electronic Publication: 2024 Sep 13 (Print Publication: 2024).
DOI:	10.1210/jendso/bvae160
Abstrakt:	Current therapeutic approaches for osteoporosis predominantly involve antiresorptive agents, but the emergence of bone anabolic therapy, such as romosozumab, presents a promising alternative. Romosozumab, a monoclonal antibody targeting sclerostin, exhibits both bone anabolic and antiresorptive effects, offering the potential to enhance bone mineral density and mitigate fracture risk. Evidence from several studies demonstrating the efficacy of romosozumab is now established in improving bone mineral density and reducing fracture rates in postmenopausal women and men. This review critically evaluates the role of romosozumab in osteoporosis management, emphasizing findings from real-world studies to facilitate its practical application in clinical settings. Adverse effects, comparative effectiveness with other osteoporotic agents, and challenges in sequential therapy are also discussed, providing insights for informed decision-making by physicians, particularly in the context of pre-treatment considerations. Additionally, the review examines global prescribing guidelines and highlights challenges associated with romosozumab utilization in special patient subgroups, aiming to optimize its clinical use. (© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu